Skip to content

Efficacy and Neural Mechanisms of Cerebellar iTBS Intervention on Craving in Individuals with Methamphetamine Dependence

Efficacy and Neural Mechanisms of Cerebellar iTBS on Craving and Cognitive Function in Individuals with Methamphetamine Dependence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108551
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine Dependence

Interventions

Treatment Group:Intermittent theta-burst stimulation (iTBS) was administered over the cerebellum, twice daily for 10 consecutive days. The iTBS parameters were as follows: an intraburst frequency of 5
Control Group:Intermittent theta-burst stimulation (iTBS) was administered over the cerebellum using a sham coil, twice daily for 10 consecutive days.

Sponsors

The First Affiliated Hospital with Nanjing Medical University / Jiangsu Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Aged 30 to 50 years (inclusive) ; 2.Meeting the diagnostic criteria for substance-induced dependence in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV); 3.History of methamphetamine dependence for more than 3 years; 4.Abstinent from drugs for at least 1 month; 5.Right-handed; 6.Education level of junior high school or above; 7.No history of drug treatment within the past 6 months; 8.No neurological or psychiatric disorders or related medical history; 9.Informed consent signed by both the participant and their legal guardian.

Exclusion criteria

Exclusion criteria: 1.History of epilepsy, family history of idiopathic epilepsy in first-degree relatives, or use of epileptogenic medications; 2.Impaired or failed function of major organs such as the heart, lungs, liver, or kidneys; 3.Severe cognitive or communication impairments that prevent cooperation; 4.Presence of a pacemaker, metallic implants in the body, or cranial defects; 5.Direct injury to the cerebellum; 6.Use of psychoactive medications—including cholinesterase inhibitors or NMDA antagonists—for treatment within at least 2 weeks prior to cognitive assessment; 7.Inability to cooperate with EEG examination.

Design outcomes

Primary

MeasureTime frame
Subjective craving score;

Secondary

MeasureTime frame
Resting-state brain connectivity measured by electroencephalography;Montreal cognitive;Task-related brain connectivity measured by electroencephalography;Working memory ;

Countries

China

Contacts

Public ContactShen Ying

The First Affiliated Hospital with Nanjing Medical University / Jiangsu Provincial People's Hospital

shenying@nimu.edu.cn+86 139 1391 3930

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026